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Rui-Xia Xu†, Sha Li†, Yan Zhang, Xiao-Lin Li, Yuan-Lin Guo, Cheng-Gang Zhu and Jian-Jun Li*Abstract
Background: Plasma PCSK9 levels was positively associated with low-density lipoprotein (LDL) cholesterol (LDL-C)
and atherosclerosis, while PCSK9 may also be implicated in the metabolism of lipoprotein subfractions. The study
was to examine the association of plasma PCSK9 with lipoprotein subfractions in patients with stable coronary artery
disease (CAD).
Methods: A total of 281 consecutive, stable CAD patients who were not treated with lipid-lowering drugs were
enrolled. The baseline clinical characteristics were collected, the plasma PCSK9 levels were determined using ELISA,
and the LDL and high-density lipoprotein (HDL) subfractions were analyzed by Lipoprint System. The association of
plasma PCSK9 levels with the lipoprotein subfractions was investigated.
Results: In the overall population, plasma PCSK9 levels were positively associated with the concentration of LDL-C,
intermediate LDL-C, small LDL-C, and LDL score, while negatively correlated with mean LDL particle size. PCSK9 levels
were positively associated with the concentration of HDL-C, intermediate HDL-C and small HDL-C. Multivariable
regression analysis revealed that the plasma PCSK9 levels were significantly and independently associated with
the concentration of intermediate LDL-C (β = 0.152, p = 0.013), small LDL-C (β = 0.179, p = 0.004), LDL score (β = 0.121,
p = 0.043), and mean LDL particle size (β = -0.130, p = 0.035), while not HDL subfractions. Interestingly, when
investigated in male and female patients separately, these relationships were only found in male but not in female,
and the small HDL-C exhibited an association with PCSK9 levels in male patients (β = 0.149, p = 0.045).
Conclusions: PCSK9 levels were independently associated with the changes of lipoprotein subfractions, suggesting a
potential interaction between PCSK9 and lipoprotein subfractions in CAD.
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Coronary artery disease (CAD) is one of the leading
causes of death worldwide. It is well known that hyper-
cholesterolemia is a major pathogenic risk factor for CAD,
and it increases the incidence of myocardial infarction and
death [1]. Proprotein convertase subtilisin kexin type 9
(PSCK9), originally discovered as a third gene involved in
autosomal dominant hypercholesterolemia [2], has gained
considerable attention over the past decade. PSCK9 is a* Correspondence: lijianjun938@126.com
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unless otherwise stated.liver-derived secreted protease which has been identified
as a key regulator of low density lipoprotein (LDL) recep-
tor (LDLR) processing [3]. PCSK9 binds directly to the
epidermal growth factor repeat A of the LDLR, subse-
quently promoting its degradation [4-7]. This process
reduces the number of LDLR, the major receptor medi-
ating the clearance of LDL-cholesterol (LDL-C), and re-
sults in increased LDL-C levels in the circulation [8,9].
In agreement with the importance of the PCSK9 for
LDL-C metabolism, a positive relationship of plasma total
cholesterol (TC), LDL-C and apolipoprotein B (apoB)
levels with plasma PCSK9 has been repeatedly demon-
strated [10].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neous particle of lipoprotein populations with respect to
size, density and chemical composition [11]. Many stud-
ies have shown that the smaller LDL particles are more
atherogenic than the larger ones, and a higher LDL par-
ticle number was consistently associated with increased
risk for cardiovascular disease independent of other lipid
measurements [12,13]. Moreover, a growing body of evi-
dence from epidemiological data, animal studies, and
clinical trials supports HDL as the next target to reduce
residual cardiovascular risk in statin-treated, high-risk
patients. However, little is known about the relationship of
plasma PSCK9 and LDL or HDL particles. The present
study was, therefore, to investigate the potential relation-
ship between plasma PCSK9 levels and LDL and HDL




The study complied with the Declaration of Helsinki
and was approved by the Ethics Committee of Fu Wai
Hospital and Cardiovascular Institute, Beijing, China. In-
formed written consent was obtained from all patients
enrolled in this study.
Study design and population
From October 2012 through February 2014, we consecu-
tively recruited 281 patients with significant CAD, which
was defined as one or more diseased epicardial vessels
with a diameter of more than 2 mm that had at least a
50% diameter stenosis by elective coronary angiography
due to angina-like chest pain and/or positive treadmill
exercise test or clinically indicated coronary computed
tomography (CT) angiography. Patients with acute cor-
onary syndrome (ACS), heart failure (The left ventricular
ejection fraction, LVEF <45%), infectious or systematic
inflammatory disease, thyroid dysfunction, severe liver
and/or renal insufficiency and malignant disease were
excluded from the current study. Inclusion criteria of
patients were as follows: 1) with definite clinical evi-
dence of atherosclerotic lesions reached to the diagnosis
criteria of CAD; 2) without treatment history of statins
and/or other lipid-lowering drugs at least 3 months prior
to entering the study; 3) with assessment for clinical his-
tory, anthropometric characteristics and standard cardio-
vascular risk factors. The definition of hypertension was
repeated blood pressure measurements ≥ 140/90 mm Hg
or currently taking anti- hypertensive drugs. Diabetes was
defined as fasting plasma glucose ≥ 7.0 mmol/ L in mul-
tiple determinations or patients were receiving an active
treatment with insulin or oral hypoglycemic agents. Dys-
lipidemia was defined as the presence of fasting TC ≥ 200
mg/dl and/or triglyceride (TG) ≥ 150 mg/dl.Laboratory examinations
Blood samples were obtained in all patients from cubital
vein after a 12-hour overnight fasting and collected into
EDTA-containing tubes. All samples were subsequently
stored at -80°C and analyzed immediately after thawing.
Concentrations of plasma TC, TG, HDL cholesterol
(HDL-C), LDL-C, apolipoprotein A-I (apoA-I), apolipo-
protein B (apoB), lipoprotein (a) [Lp (a)], and free fatty
acid (FFA) were measured using an automatic biochem-
istry analyzer (Hitachi 7150, Tokyo, Japan). Of which,
TC, TG, HDL-C, LDL-C, and FFA levels were measured
by enzymatic assay. ApoA-I, apoB, and Lp (a) levels
were measured by turbidimetric immunoassay. Plasma
PCSK9 concentrations were measured using a high sen-
sitivity, quantitative sandwich enzyme-linked immuno-
sorbent assay (CircuLex ELISA, CycLex Co., Nagano,
Japan). The mean minimum detectable dose of PCSK9
was 0.154 ng/ml.
LDL subfraction analysis
Blood samples were also used for subfraction analysis.
LDL subfraction analysis was performed electrophoretic-
ally by the use of high-resolution 3% polyacrylamide gel
tubes and the Lipoprint LDL System (Quantimetrix
Corporation, Redondo Beach, CA, USA) according to
the manufacturer’s instructions as previously described
[14,15]. This method was based on electrophoresis of a
liquid loading gel with lipophilic dye in the precast lin-
ear polyacrylamide gel (stacking gel and separating gel).
A typical Lipoprint profile of decreasing size and
increasing density with 1 very low density lipoprotein
(VLDL) band, 3 Midbands, up to 7 LDL bands, and 1
HDL band was obtained. The various stained bands
(lipoprotein subfractions) presented in the sample were
indentified by their electrophoretic mobility (Rf ) using
VLDL as the starting reference point (VLDL = 0) and
HDL as the leading reference point (HDL = 1). The
relative area for each lipoprotein subfraction was deter-
mined and multiplied by TC concentration of the sample
to yield the amount of cholesterol for each band in mg/dl.
As a result, the cholesterol mass of each LDL subfraction
and the mean LDL particle size (Å) were calculated on
the basis of the different areas under the curve with dif-
ferent Rf. Subfraction 1 represented large LDL particles,
subfraction 2 indicated intermediate LDL particles, and
subfraction 3-7 meant small LDL particles. The propor-
tion of sd-LDL particles (subfractions 3–7) to the whole
LDL area (subfractions 1–7) was also calculated in our
sample (LDL score).
HDL subfraction analysis
Similar to LDL subfraction analysis, the cholesterol
contents of HDL subfractions were also determined
electrophoretically by the use of high-resolution 3%
Table 1 Baseline characteristics of the study population
Characteristics Patients (n = 281)
Demographics
Age (years) 57.97 ± 9.55
Men [n (%)] 199 (70.8)
BMI (kg/m2) 25.96 ± 3.42
Coronary risk factors
Hypertension [n (%)] 190 (67.6)
Diabetes [n (%)] 75 (26.7)
Dyslipidemia [n (%)] 197 (70.1)
Smoking [n (%)] 139 (49.5)
Family history of CAD [n (%)] 52 (18.5)
Laboratory parameters
TC (mg/dl) 190.23 ± 43.09
TG (mg/dl) 147.79 (104.87-207.96)
Non-HDL-C (mg/dl) 147.77 ± 41.85
Apo A-I (g/L) 1.39 ± 0.26
Apo B (g/L) 1.00 ± 0.28
LDL-C (mg/dl) 122.91 ± 38.87
Large LDL-C (mg/dl) 27.76 ± 9.66
Intermediate LDL-C (mg/dl) 20.81 ± 9.26
Small LDL-C (mg/dl) 9.29 ± 9.97
LDL score (% of sd-LDL) 14.48 ± 13.56
Mean LDL size (Å) 266.06 ± 6.10
HDL-C (mg/dl) 42.46 ± 14.68
Large HDL-C (mg/dl) 13.70 ± 7.50
Intermediate HDL-C (mg/dl) 20.90 ± 7.35
Small HDL-C (mg/dl) 8.17 ± 3.49
ALT (U/L) 24.92 ± 17.34
AST (U/L) 18.54 ± 8.72
ALP (IU/L) 64.67 ± 17.78
GGT (IU/L) 33.56 ± 23.96
Cr (μmol/L) 72.38 ± 16.63
BUN (mmol/L) 5.94 ± 1.47
PCSK9 (ng/ml) 215.53 (180.14-260.39)
The data shown are the mean ± SD, median (Q1-Q3 quartiles) or n (%).
BMI: body mass index. CAD: coronary artery disease. TC: total cholesterol.
TG: triglycerides. Non-HDL-C: non high-density lipoprotein cholesterol. ApoA-I:
apolipoprotein A1. ApoB: apolipoprotein B. LDL-C: low-density lipoprotein-
cholesterol. HDL-C: high-density lipoprotein cholesterol. ALT: alanine
aminotransferase. AST: aspartate aminotransferase. ALP: alkaline phosphatase.
GGT: glutamyl transferase. Cr: creatinine. BUN: blood urea nitrogen. PSCK9:
proprotein convertase subtilisin kexin type 9.
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(Quantimetrix Corporation, Redondo Beach, CA, USA) as
previously described [14]. After the electrophoresis was
completed, the various stained HDL subfractions (bands)
presented presented in the sample were indentified by Rf
using LDL/VLDL as the starting reference point (LDL/
VLDL = 0) and Albumin as the leading reference point
(Albumin = 1). The relative area for each HDL subfraction
was determined and multiplied by HDL-C concentration
of the sample to yield the amount of cholesterol for each
band in mg/dl. Using this assay, HDL was divided into 10
subfractions. Subfraction 1-3 represented large HDL
particles, subfraction 4-7 indicated intermediate HDL
particles, and subfraction 8-10 mean small HDL particles.
Statistical analysis
The data are expressed as mean ± standard deviation or
median (Q1-Q3 quartiles) for continuous variables and
number (percentage) for categorical variables. The Mann-
Whitney U test was used for the comparison of clinical
parameters between two groups. The categorical variables
were compared using the chi-square test. A linear uni-
variable regression analysis was performed to determine
the relationship between PCSK9 levels and lipoprotein
subfractions. Multivariable regression analysis was used
to assess the independent contribution of the variables.
A p-value < 0.05 was considered statistically significant.
Statistical analysis was performed with SPSS version
19.0 software (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
We enrolled 281 patients with stable CAD in this study.
Their clinical characteristics, plasma PCSK9 levels, (apo)
lipoproteins and lipoprotein subfractions are shown in
Table 1. The mean age of the study population was
57.97 ± 9.55 years, and 70.8% of the patients were men.
The plasma PCSK9 levels ranged from 99.23 to 477.70
ng/ml, and the distribution of PCSK9 levels in this
population was right-skewed (median: 215.53 ng/ml).
Correlations of plasma PCSK9 levels with lipid profile and
lipoprotein subfractions
For the Spearman correlation analysis, plasma PCSK9 was
not only correlated positively with TC, LDL-C, apo B,
non-HDL-C, but also with HDL-C and apo A-I (Table 2)
in overall population. However, PCSK9 was unrelated to
TG. Furthermore, PCSK9 was positively correlated with
intermediate, small LDL-C, and LDL score (intermediate
LDL-C r = 0.145, p = 0.015; small LDL-C r = 0.166, p =
0.005; LDL score r = 0.120, p = 0.046), while not with large
LDL-C and mean LDL particle size (large LDL-C r =
0.089, p = 0.140; mean LDL particle size r = -0.104, p =
0.084). A positive relationship between PCSK9 andintermediate and small HDL-C was also observed in
our study (r = 0.157, p = 0.013; r = 0.124, p = 0.048; re-
spectively). However, there were no significant associa-
tions between the PCSK9 levels and age, body mass
index (BMI), blood pressure, and plasma glucose levels.
Table 2 Univariable correlations of PCSK9 with lipid
profile and lipoprotein subfractions in patients with CAD
Variables r P-value
Age (years) 0.006 0.924
BMI (kg/m2) -0.064 0.287
SBP (mm Hg) -0.080 0.180
DBP (mm Hg) -0.034 0.568
Glucose (mmol/L) 0.047 0.434
TC (mg/dl) 0.249 0.000
TG (mg/dl) 0.075 0.213
Non-HDL-C (mg/dl) 0.221 0.000
Apo A-I (g/L) 0.184 0.003
Apo B (g/L) 0.260 0.000
LDL-C (mg/dl) 0.219 0.000
Large LDL-C (mg/dl) 0.089 0.140
Intermediate LDL-C (mg/dl) 0.145 0.015
Small LDL-C (mg/dl) 0.166 0.005
LDL score (% of sd-LDL) 0.120 0.046
Mean LDL size (Å) -0.104 0.084
HDL-C (mg/dl) 0.149 0.012
Large HDL-C (mg/dl) 0.045 0.476
Intermediate HDL-C (mg/dl) 0.157 0.013
Small HDL-C (mg/dl) 0.124 0.048
Spearman correlation analysis is shown. The bold values indicate statistical
significance and are bolded to improve the readability of the table.
BMI: body mass index. SBP: systolic blood pressure. DBP: diastolic blood
pressure. TC: total cholesterol. TG: triglycerides. Non-HDL-C: non high-density
lipoprotein cholesterol. ApoA-I: apolipoprotein A1. ApoB: apolipoprotein B.
LDL-C: low-density lipoprotein-cholesterol. HDL-C: high-density lipoprotein
cholesterol.
Table 3 Independent associations of the PCSK9 levels
with the lipid profile and lipoprotein subfractions in
patients with CAD
Variables Multivariable linear regression
analysis
Coefficients P-value
TC (mg/dl) 0.215 0.000
TG (mg/dl) 0.042 0.494
Non-HDL-C (mg/dl) 0.202 0.001
Apo A-I (g/L) 0.137 0.025
Apo B (g/L) 0.245 0.000
LDL-C (mg/dl) 0.197 0.001
Large LDL-C (mg/dl) 0.033 0.590
Intermediate LDL-C (mg/dl) 0.152 0.013
Small LDL-C (mg/dl) 0.179 0.004
LDL score (% of sd-LDL) 0.121 0.043
Mean LDL size (Å) -0.130 0.035
HDL-C (mg/dl) 0.056 0.334
Large HDL-C (mg/dl) -0.050 0.380
Intermediate HDL-C (mg/dl) 0.069 0.276
Small HDL-C (mg/dl) 0.062 0.332
The multivariable linear regression analysis was adjusted for age, gender, BMI,
hypertension, diabetes mellitus, current smoking and positive family history.
The lipids and lipoprotein subfractions were the dependent variables.
TC: total cholesterol. TG: triglycerides. Non-HDL-C: non high-density lipoprotein
cholesterol. ApoA-I: apolipoprotein A1. ApoB: apolipoprotein B. LDL-C: low-density
lipoprotein-cholesterol. HDL-C: high-density lipoprotein cholesterol.
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PCSK9 levels with lipids and lipoprotein subfractions in
patients with stable CAD, we performed a multivariable
linear regression analysis (Table 3). After adjustment for
age, gender, BMI, hypertension, diabetes mellitus and
positive family history, PCSK9 was significantly related
with TC (β = 0.215, p < 0.001), LDL-C (β = 0.197, p =
0.001), apo B (β = 0.245, p < 0.001), apo A-I (β = 0.137, p =
0.025), intermediate LDL-C (β = 0.152, p = 0.013), small
LDL-C (β = 0.179, p = 0.004), and LDL score (β = 0.121,
p = 0.043). Interestingly, a negative association between
PCSK9 and mean LDL size arose (β = -0.130, p = 0.035)
after adjustment for above confounders. However, the
relationship between PCSK9 and each HDL subtraction
vanished (Table 3) after the adjustment.
Gender analysis in the correlations of plasma PCSK9 with
lipid profile and lipoprotein subfractions
A gender comparison of the relationship between the
PCSK9 and lipids and lipoprotein subfractions was also
performed in the present study due to the reportedgender differences in prevalence of CAD and levels of
PCSK9. As presented in Table 4, women with stable
CAD had not only an older age of onset and more sig-
nificant disturbances in their lipid profiles, but also
higher PCSK9 levels compared to men.
In the present study, we found no significant correl-
ation of the PCSK9 levels with the cholesterol concen-
tration of LDL and HDL subfractions in women, even
with bivariable correlation analysis (data not shown).
However, in men, there were positive relationships be-
tween the PCSK9 levels and the concentrations of TC
(β = 0.264, p < 0.001), TG (β = 0.212, p < 0.001), non-
HDL-C (β = 0.251, p < 0.001), apo A-I (β = 0.164, p =
0.020), apo B (β = 0.253, p < 0.001), LDL-C (β = 0.216, p =
0.002), intermediate LDL-C (β = 0.167, p = 0.018), small
LDL-C (β = 0.212, p = 0.003) and mean LDL particle size
(β = -0.168, p = 0.018), as well as small HDL-C (β = 0.204,
p = 0.006) (Figure 1). Furthermore, after adjusting for the
traditional risk factors such as age, BMI, hypertension,
diabetes mellitus, current smoking and positive family
history, there remained significant correlations of the
PCSK9 levels with TC (β = 0.289, p < 0.001), TG (β =
0.148, p = 0.031), non-HDL-C (β = 0.264, p < 0.001), apo
A-I (β = 0.223, p = 0.001), apo B (β = 0.269, p < 0.001),
LDL-C (β = 0.230, p = 0.001), intermediate LDL-C (β =
Table 4 Comparisons of the clinical characteristics between male and female patients with CAD
Variables Male (n = 199) Female (n = 82) P-value
Age (years) 56.79 ± 9.32 60.84 ± 9.56 0.001
BMI (kg/m2) 26.20 ± 3.14 25.35 ± 3.99 0.088
Hypertension [n (%)] 135 (67.8) 55 (67.1) 0.890
Diabetes [n (%)] 53 (26.6) 22 (26.8) 0.973
Dyslipidemia [n (%)] 135 (67.8) 62 (75.6) 0.251
Smoking [n (%)] 134 (67.3) 5 (6.1) 0.000
Family history of CHD [n (%)] 30 (15.1) 22 (26.8) 0.028
TC (mg/dl) 183.73 ± 40.76 205.99 ± 44.72 0.000
TG (mg/dl) 147.79 (106.19-208.85) 146.02 (98.23-207.30) 0.428
Non-HDL-C (mg/dl) 144.24 ± 40.11 156.33 ± 44.92 0.027
Apo A-I (g/L) 1.34 ± 0.21 1.52 ± 0.31 0.000
Apo B (g/L) 0.98 ± 0.27 1.07 ± 0.30 0.019
LDL-C (mg/dl) 110.07 ± 37.09 134.65 ± 40.78 0.001
Large LDL-C (mg/dl) 26.80 ± 9.35 30.10 ± 10.05 0.009
Intermediate LDL-C (mg/dl) 20.58 ± 9.01 21.38 ± 9.87 0.512
Small LDL-C (mg/dl) 9.49 ± 10.57 8.79 ± 8.37 0.593
LDL score (% of sd-LDL) 14.92 ± 14.23 13.42 ± 11.75 0.366
Mean LDL size (Å) 265.74 ± 6.44 266.85 ± 5.15 0.168
HDL-C (mg/dl) 39.49 ± 11.68 49.67 ± 18.37 0.000
Large HDL-C (mg/dl) 12.10 ± 5.40 17.49 ± 10.05 0.000
Intermediate HDL-C (mg/dl) 19.76 ± 6.27 23.60 ± 8.91 0.001
Small HDL-C (mg/dl) 7.99 ± 3.57 8.59 ± 3.28 0.214
PCSK9 (ng/ml) 205.21 (174.32-247.02) 236.93 (193.10-283.64) 0.000
BMI: body mass index. TC: total cholesterol. TG: triglycerides. Non-HDL-C: non high-density lipoprotein cholesterol. ApoA-I: apolipoprotein A1. ApoB: apolipoprotein
B. LDL-C: low-density lipoprotein-cholesterol. HDL-C: high-density lipoprotein cholesterol.
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LDL score (β = 0.177, p = 0.015), mean LDL particle size
(β = -0.174, p = 0.015) and small HDL-C (β = 0.149, p =
0.045) (Table 5).
Discussion
The major finding of the present study was that the
plasma PCSK9 levels were positively and independently
associated with intermediate and small LDL subfractions
but not large LDL subfraction in patients with stable
CAD. Interestingly, our study firstly found these associa-
tions were significantly only in men but not in women,
suggesting the interacting impact of PCSK9 with lipo-
protein subfractions may be a novel mechanism for
gender disparity in the development of CAD.
PCSK9 is an enzyme with an important role in lipo-
protein metabolism [16]. In human, gain-of-function
mutations in the PCSK9 gene caused a high LDL-C
level and a form of familial hypercholesterolemia [17],
whereas loss-of-function variants lead to a low LDL-C
level and a reduced incidence of CAD [18,19]. The
positive associations of the plasma PCSK9 levels withTC and LDL-C were previously observed in patients
with familial hypercholesterolemia and CAD [20,21],
even in the healthy subjects [22,23]. Recently, studies
have shown that circulating PCSK9 levels were signifi-
cantly correlated with TC, LDL-C and non-HDL-C
[10,24,25]. As anticipated, in the present study, we ob-
served strong positive correlations of plasma PSCK9
with TC, non-HDL-C, LDL-C, apo B levels. We also
found that PCSK9 was not correlated positively with
TG levels, which was in disagreement with previous
data [25,26]. Mayne et al showed that plasma PCSK9
levels were positively correlated with TC and LDL-C in
male normolipidemic subjects but not in female [27].
Similarly, our study also demonstrated that PCSK9 was
significantly associated with TC, LDL-C and non-HDL-
C in male patients with CAD while not in female, sug-
gesting that a gender difference in PCSK9 regulation
and function with PCSK9 correlated to TC and LDLC
in men but not women. The explanation for these gender
differences is unknown. Previous studies demonstrated
that estrogen augmented LDL receptor levels, while an-
drogens attenuated these effects [28,29], although the
Figure 1 Correlations of the plasma PCSK9 levels with lipid profile and lipoprotein subfractions in male patients with CAD.
Spearman correlation analysis was shown for the association of PCSK9 with TC (A), TG (B), non-HDL-C (C), Apo A-I (D), Apo B (E), LDL-C (F),
intermediate LDL-C (G), small LDL-C (H), mean LDL particle size (I) and small HDL-C (J).
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Table 5 Independent associations of the PCSK9 levels with the lipid profile and lipoprotein subfractions across gender
Variables Multivariable linear regression analysis
Male Female
Coefficients P-value Coefficients P-value
TC (mg/dl) 0.289 0.000 0.042 0.733
TG (mg/dl) 0.148 0.031 -0.160 0.183
Non-HDL-C (mg/dl) 0.264 0.000 0.033 0.787
Apo A-I (g/L) 0.223 0.001 0.050 0.683
Apo B (g/L) 0.269 0.000 0.146 0.233
LDL-C (mg/dl) 0.230 0.001 0.065 0.587
Large LDL-C (mg/dl) -0.006 0.929 0.140 0.248
Intermediate LDL-C (mg/dl) 0.183 0.009 0.041 0.739
Small LDL-C (mg/dl) 0.240 0.001 -0.063 0.605
LDL score (% of sd-LDL) 0.177 0.015 -0.060 0.603
Mean LDL size (Å) -0.174 0.015 0.030 0.806
HDL-C (mg/dl) 0.100 0.157 0.021 0.862
Large HDL-C (mg/dl) -0.044 0.550 -0.074 0.502
Intermediate HDL-C (mg/dl) 0.087 0.253 0.043 0.730
Small HDL-C (mg/dl) 0.149 0.045 -0.172 0.166
The multivariable linear regression analysis was adjusted for age, BMI, hypertension, diabetes mellitus, current smoking and positive family history. The lipids and
lipoprotein subfractions are the dependent variables.
TC: total cholesterol. TG: triglycerides. Non-HDL-C: non high-density lipoprotein cholesterol. ApoA-I: apolipoprotein A1. ApoB: apolipoprotein B. LDL-C: low-density
lipoprotein-cholesterol. HDL-C: high-density lipoprotein cholesterol.
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or translation have not been studied.
It has been demonstrated that the changes of lipopro-
tein subfractions are strongly related the increased risk of
CAD [30,31]. The major novel findings are that plasma
PCSK9 levels were significantly and independently associ-
ated with the cholesterol concentrations of intermediate
and small LDL subfractions as well as mean LDL particle
size in patients with stable CAD. Actually, circulating LDL
as well as HDL consists of a heterogeneous group of
particles with respect to size, density, and chemical com-
position [32]. The differences of LDL particles lead to the
recognition of two distinct phenotypes: phenotype A,
associated with large, buoyant LDL particles (lb-LDL); and
phenotype B, in which small and dense LDL particles (sd-
LDL) predominate [33]. Presently, the small LDL particles
have been recognized more atherogenic than large ones
and can predict atherosclerosis progression and incident
CHD [33,34]. Recently, Kwakernaak et al found that
plasma PCSK9 was significantly correlated with LDL
particle concentrations, and was independently related to
intermediate density lipoprotein (IDL) by nuclear mag-
netic resonance spectroscopy analysis in healthy subjects
[25]. A new study demonstrated that men with higher
PCSK9 levels did not have higher cholesterol in large or
medium size LDL particles, but had higher cholesterol
levels in small LDL particles, indicating that plasma
PCSK9 levels were modestly associated with LDL particlesize in abdominally obese, dyslipidemic men [35]. Appar-
ently, our results confirmed and extended previous study,
suggesting that PCSK9 predominantly related to the
metabolism of intermediate and small LDL particles in
patients with CAD.
The associations of plasma PCSK9 with HDL subfrac-
tions are not well characterized, although the emerging
opinion is that the quality of HDL particles may be more
important than the quantity of HDL for the develop-
ment of CAD. Several recent studies in mice and non-
human primates have shown that PCSK9 is involved in
HDL metabolism. B6 male mice fed a high fat diet and
then treated with a Pcsk9 antisense oligonucleotide
inhibitor for 6 weeks showed a 54% reduction in HDL
cholesterol concentration [36]. In male cynomolgus ma-
caques, treatment with neutralizing antibodies against
PCSK9 reduced HDL cholesterol concentrations for the
first seven days of treatment [37]. To our knowledge,
our data firstly found that plasma PCSK9 levels were
positively associated with HDL-C in human study. In
male CAD patients not female, PCSK9 was positively
correlated with the concentration of small HDL-C. The
mechanism underlying this observation was not com-
pletely understood.
Numerous studies have now suggested a remark gender
difference concerning the clinical characteristics of CAD
[38-40]. Women with CAD were more likely to have
cardiovascular risk factors but a milder atheroma burden
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http://www.lipidworld.com/content/13/1/188than men [39]. Women developed CAD when they are
about ten years older than men and, typically, after meno-
pause [41]. Though the risk of CAD is greater in men than
that in women, the exact mechanisms are not fully under-
stood. LDL becomes more atherogenic and toxic as its
particle size decreases and its electronegativity increases
[42]. A recent study found that LDL electronegativity is
higher in male patients with metabolic syndrome (MetS)
than female patients with MetS, which underlie the
increased propensity to CAD observed in male patients
[43]. Previous study showed that increased sdLDL fraction
and decreased LDL particle size were positively correlated
with the extent and severity of CAD [30]. Pitavastatin
improved LDL subfraction profiles, and this in turn may
reduced the cardiovascular risk in patients with type 2
diabetes and dyslipidemia [44]. PCSK9 is an important
regulator of LDL-C concentrations in plasma, which was
found significantly different between male and female
[27,45]. Therefore, we further examine the gender disparities
for the relationships between PCSK9 and lipoprotein
subfractions. Interestingly, our data firstly found that PCSK9
was positively and independently associated with intermedi-
ate LDL-C, small LDL-C, and small HDL-C, while nega-
tively with LDL particle size in male patients with CAD, but
not in female. This finding may have important clinical im-
plication in spite of unknown exact mechanisms. Whether it
is a potential cause for explanation the gender differences in
the development of CAD appear attractive for further study.
There were several limitations of the present study. First,
it is a cross-sectional study of patients referred for coronary
angiography. Second, the relative small sample size from a
single center may limit the ability to detect weak correlations
in both univariable and multivariable analysis. Finally, the
study population represents an inhomogeneous cohort with
regard to gender. Therefore, the results of our study should
careful explanation and needed to be further investigation.
Summarily, in the present study, plasma PCSK9 level
was independently positively associated with the choles-
terol concentration of intermediate and small LDL
subfractions and LDL particle size in patients with stable
CAD. An analysis across gender showed that this relation-
ship was only found in male patients but not in female,
suggesting the interacting impact of PCSK9 with lipo-
protein subfractions may be a novel mechanism for gender
disparity in the development of CAD. Whether this impact
has a causal effects may be needed to further evaluate.
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